康龍化成(03759.HK):完成康龍生物增資
格隆匯9月20日丨康龍化成(03759.HK)發佈公吿,有關康龍化成(寧波)生物醫藥有限公司(“康龍生物”)增資。增資協議項下的所有先決條件已獲滿足,且應由所有相關投資者(除華傑高景外)支付的人民幣款項,以及應由華傑高景支付的美元款項,已分別於2023年5月5日及2023年9月19日完成。康龍生物亦已在相關市場監管部門完成相關登記手續並取得更新的營業執照。因此,增資已完成。增資的最終對價約為人民幣9.50億元。增資完成後,康龍生物已成為公司的非全資附屬公司,而康龍生物的財務業績仍將併入公司的財務業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.